Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 174

1.

Twelve to 24-month-olds can understand the meaning of morphological regularities in their language.

Ferry A, Nespor M, Mehler J.

Dev Psychol. 2020 Jan;56(1):40-52. doi: 10.1037/dev0000845. Epub 2019 Dec 2.

PMID:
31789528
2.

An embryonic CaVβ1 isoform promotes muscle mass maintenance via GDF5 signaling in adult mouse.

Traoré M, Gentil C, Benedetto C, Hogrel JY, De la Grange P, Cadot B, Benkhelifa-Ziyyat S, Julien L, Lemaitre M, Ferry A, Piétri-Rouxel F, Falcone S.

Sci Transl Med. 2019 Nov 6;11(517). pii: eaaw1131. doi: 10.1126/scitranslmed.aaw1131.

PMID:
31694926
3.

Access to C-aryl/alkenylglycosides by directed Pd-catalyzed C-H functionalisation of the anomeric position in glycal-type substrates.

de Robichon M, Bordessa A, Malinowski M, Uziel J, Lubin-Germain N, Ferry A.

Chem Commun (Camb). 2019 Sep 26;55(78):11806-11808. doi: 10.1039/c9cc05993h.

PMID:
31532405
4.

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.

Klein AF, Varela MA, Arandel L, Holland A, Naouar N, Arzumanov A, Seoane D, Revillod L, Bassez G, Ferry A, Jauvin D, Gourdon G, Puymirat J, Gait MJ, Furling D, Wood MJ.

J Clin Invest. 2019 Nov 1;129(11):4739-4744. doi: 10.1172/JCI128205.

5.

Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice.

Lu-Nguyen N, Ferry A, Schnell FJ, Hanson GJ, Popplewell L, Dickson G, Malerba A.

Hum Mol Genet. 2019 Sep 15;28(18):3091-3100. doi: 10.1093/hmg/ddz125.

PMID:
31179493
6.

Contributing factors and outcomes of burn-associated cholestasis.

de Tymowski C, Dépret F, Soussi S, Nabila M, Vauchel T, Chaussard M, Benyamina M, Ferry A, Cupaciu A, Jully M, Oueslati H, Fratani A, Coutrot M, Sogni P, Mimoun M, Chaouat M, Zagdanski AM, De Kerviler E, Mebazaa A, Moreau R, Mallet V, Legrand M; PRONOBURN group.

J Hepatol. 2019 Sep;71(3):563-572. doi: 10.1016/j.jhep.2019.05.009. Epub 2019 May 30.

PMID:
31152758
7.

Effects of the selective inhibition of proteasome caspase-like activity by CLi a derivative of nor-cerpegin in dystrophic mdx mice.

Hovhannisyan Y, Melikyan G, Mougenot N, Gao-Li J, Friguet B, Paulin D, Li Z, Ferry A, Agbulut O.

PLoS One. 2019 Apr 23;14(4):e0215821. doi: 10.1371/journal.pone.0215821. eCollection 2019.

8.

A standardized methodical approach to characterize the influence of key parameters on the in vitro efficacy of extracorporeal photopheresis.

Laulhé M, Lefebvre S, Le Broc-Ryckewaert D, Pierre M, Ferry A, Delorme B.

PLoS One. 2019 Mar 1;14(3):e0212835. doi: 10.1371/journal.pone.0212835. eCollection 2019.

9.

"CO" as a Carbon Bridge to Build Complex C2-Branched Glycosides Using a Palladium-Catalyzed Carbonylative Suzuki-Miyaura Reaction from 2-Iodoglycals.

de Robichon M, Bordessa A, Lubin-Germain N, Ferry A.

J Org Chem. 2019 Mar 15;84(6):3328-3339. doi: 10.1021/acs.joc.8b03248. Epub 2019 Feb 28.

PMID:
30793601
10.

Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: A targeted machine learning analysis.

Vauchel T, Pirracchio R, Chaussard M, Lafaurie M, Rouveau M, Rousseau C, Benyamina M, Soussi S, Dépret F, Ferry A, Oueslati H, Chaouat M, Mimoun M, Jarlier V, Moreno N, Mebazaa A, Legrand M.

Am J Infect Control. 2019 Apr;47(4):435-438. doi: 10.1016/j.ajic.2018.09.010. Epub 2018 Nov 29.

PMID:
30503627
11.

Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study.

Dudoignon E, Alanio A, Anstey J, Depret F, Coutrot M, Fratani A, Jully M, Cupaciu A, Chaussard M, Oueslati H, Ferry A, Benyamina M, de Tymowski C, Boccara D, Serror K, Chaouat M, Mimoun M, Lafaurie M, Denis B, Gits-Muselli M, Bretagne S, Mebazaa A, Legrand M, Soussi S; PRONOBURN group.

Mycoses. 2019 Mar;62(3):237-246. doi: 10.1111/myc.12872. Epub 2018 Dec 18.

PMID:
30478963
12.

Prediction of major adverse kidney events in critically ill burn patients.

Dépret F, Boutin L, Jarkovský J, Chaussard M, Soussi S, Bataille A, Oueslati H, Moreno N, de Tymowski C, Parenica J, Benešová K, Vauchel T, Ferry A, Benyamina M, Cupaciu A, Coutrot M, Garnier JP, Serror K, Chaouat M, Mebazaa A, Legrand M; PRONOBURN group.

Burns. 2018 Dec;44(8):1887-1894. doi: 10.1016/j.burns.2018.08.007. Epub 2018 Oct 12.

PMID:
30322739
13.

Aged Nicotinamide Riboside Kinase 2 Deficient Mice Present an Altered Response to Endurance Exercise Training.

Deloux R, Tannous C, Ferry A, Li Z, Mericskay M.

Front Physiol. 2018 Sep 19;9:1290. doi: 10.3389/fphys.2018.01290. eCollection 2018.

14.

The Paradoxical Role of NKG2D in Cancer Immunity.

Sheppard S, Ferry A, Guedes J, Guerra N.

Front Immunol. 2018 Aug 13;9:1808. doi: 10.3389/fimmu.2018.01808. eCollection 2018. Review.

15.

Improvement of Dystrophic Muscle Fragility by Short-Term Voluntary Exercise through Activation of Calcineurin Pathway in mdx Mice.

Delacroix C, Hyzewicz J, Lemaitre M, Friguet B, Li Z, Klein A, Furling D, Agbulut O, Ferry A.

Am J Pathol. 2018 Nov;188(11):2662-2673. doi: 10.1016/j.ajpath.2018.07.015. Epub 2018 Aug 22.

PMID:
30142334
16.

[Conclusions of the RARE 2017 meeting].

Triclin-Conseil N, Aymé S, Ferry A.

Med Sci (Paris). 2018 May;34 Hors série n°1:60. doi: 10.1051/medsci/201834s131. Epub 2018 Jun 18. French. No abstract available.

17.

[The RARE 2017 meeting for companies developing products for rare patients].

Ferry A.

Med Sci (Paris). 2018 May;34 Hors série n°1:7. doi: 10.1051/medsci/201834s104. Epub 2018 Jun 18. French. No abstract available.

18.

Synthesis of C-pyrimidyl nucleosides starting from alkynyl ribofuranosides.

Legrave G, Youcef RA, Afonso D, Ferry A, Uziel J, Lubin-Germain N.

Carbohydr Res. 2018 Jun 15;462:50-55. doi: 10.1016/j.carres.2018.04.005. Epub 2018 Apr 13.

PMID:
29684691
19.

Risk Factors for Acute Mesenteric Ischemia in Critically Ill Burns Patients-A Matched Case-Control Study.

Soussi S, Taccori M, De Tymowski C, Depret F, Chaussard M, Fratani A, Jully M, Cupaciu A, Ferry A, Benyamina M, Serror K, Boccara D, Chaouat M, Mimoun M, Cattan P, Zagdanski AM, Anstey J, Mebazaa A, Legrand M; PRONOBURN group.

Shock. 2019 Feb;51(2):153-160. doi: 10.1097/SHK.0000000000001140.

PMID:
29561390
20.

Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.

Trochet D, Prudhon B, Beuvin M, Peccate C, Lorain S, Julien L, Benkhelifa-Ziyyat S, Rabai A, Mamchaoui K, Ferry A, Laporte J, Guicheney P, Vassilopoulos S, Bitoun M.

EMBO Mol Med. 2018 Feb;10(2):239-253. doi: 10.15252/emmm.201707988.

Supplemental Content

Loading ...
Support Center